证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-038 江苏鱼跃医疗设备股份有限公司 第六届董事会第九次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 2024 年 12 月 25 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯 表决的方式召开了第六届董事会第九次临时会议。公司于 2024 年 12 月 20 日以书面送 达及电子邮件方式向公司全体董事发出了召开公司第六届董事会第九次临时会议的通 知以及提交审议的议案。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议的召 集、召开及表决等程序符合《中华人民共和国公司法》和《公司章程》的有关规定，会 议决议合法、有效。会议由董事长吴群先生主持，经与会董事充分讨论，审议通过了如 下议案： 二、董事会会议审议情况 1、关于《公司开展外汇套期保值业务》的议案 表决结果：同意：9 票；反对：0 票；弃权：0 票 董事会同意授权公司管理层行使该项业务决策权并由财务部门负责具体事宜，授权 期限自第六届董事会第九次临时会议审议通过之日起 12 个月 ...

Company and Industry Summary Company Overview - The company has shown a recovery in revenue growth, achieving positive year-on-year growth in Q1 after a challenging previous year due to the pandemic [1] - The company maintained a stable average selling price and increased market share despite overall consumer pressure [1] - A significant decline in scale was noted in the first three quarters, primarily due to a one-time asset disposal gain from the previous year, estimated at around 500 to 600 million [1] E-commerce and Market Position - The company maintained its market position during the Double Eleven shopping festival, with an increase in market share in key categories [2][4] - Sales volume during Double Eleven was not directly comparable to the previous year due to a longer sales period this year [3] - Consumer sentiment indicated that discounts during Double Eleven were perceived as insufficient, impacting overall sales performance [3] Product Performance - Major product categories such as oxygen machines and blood pressure monitors showed stable growth, while other categories like electronic blood pressure monitors and sleep apnea machines are experiencing rapid market share growth [5] - The company is included in a government subsidy program for aging products, which could enhance sales, although the impact has been limited so far [6][7] - The subsidy program has a maximum support rate of 70% to 80% for eligible products, but its effectiveness varies by region [6] Capital Expenditure and Financial Strategy - The company has completed significant capital expenditures, including 3.5 billion for land and factory investments, with no major new expenditures planned in the short term [11][12] - The company maintains a dividend payout ratio of over 30% and has consistently paid dividends since its IPO in 2008, but plans to focus on expanding overseas markets instead of increasing dividends [13] International Expansion - The company is focusing on expanding its presence in developing countries, particularly in Southeast Asia and South America, where it sees significant growth potential [14][15] - In developed markets, the company faces challenges due to established brands and a more closed market structure, but it is working on product entry and brand recognition [16][18] - The company aims to leverage its competitive pricing and product differentiation to penetrate these markets [19] Future Outlook - The company anticipates stable growth in domestic sales, particularly in established product categories, while expecting higher growth rates in overseas markets [22] - The company is also focusing on product upgrades and new product launches to enhance its market position and profitability [27][28] - The overall economic environment is expected to stabilize, which may improve consumer spending and sales performance in the coming year [36] Key Risks and Considerations - The company faces macroeconomic pressures that could impact consumer spending and overall sales performance [26] - The effectiveness of government subsidies and their expansion into new regions will be crucial for driving sales growth [7][9] - The competitive landscape in both domestic and international markets remains challenging, requiring continuous innovation and strategic positioning [19][20]

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-037 江苏鱼跃医疗设备股份有限公司 关于 2023 年度员工持股计划预留部分 非交易过户完成的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）于 2024 年 10 月 15 日召开第六届董事会第六次临时会议，审议通过了《关于公司 2023 年度员工持股计划预留份额分配的议案》。具体内容详见公司于 2024 年 10 月 16 日披露在《证券时报》及巨潮资讯网（www.cninfo.com.cn）上的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》的相关规定，现将公 司 2023 年度员工持股计划（以下简称"本次员工持股计划"）实施进展情况公告 如下： 一、本次员工持股计划基本情况 二、本次员工持股计划预留部分认购和非交易过户情况 本次员工持股计划股票来源于公司 2021 年 2 月 23 日至 2022 年 1 月 28 日 专用证券账户回购的 ...

Group 1: General Principles of Investor Relations Management - The purpose of investor relations management is to enhance communication between the company and investors, ensuring transparency and protecting investor rights [1][2] - Key objectives include fostering a positive relationship with investors, establishing a stable investor base, and improving corporate governance [1][3] - The management principles emphasize compliance, equality, proactivity, and integrity in all investor relations activities [2][3] Group 2: Content and Methods of Investor Relations Management - Communication with investors should cover the company's development strategy, legal disclosures, management information, and risk factors [3][4] - A comprehensive record of investor relations activities must be maintained, including participant details and communication content [3][4] - Multiple channels and platforms should be utilized for investor communication, including the company website, social media, and direct meetings [4][5] Group 3: Information Disclosure and Meetings - The company must adhere to legal requirements for timely and accurate information disclosure, avoiding misleading statements [5][6] - Shareholder meetings should be accessible, especially for minority shareholders, and may include online voting options [5][6] - Investor briefings should be held to discuss financial performance and address investor inquiries, with the chairman or CEO typically present [6][7] Group 4: Research and Interaction with Analysts - The company must ensure that research activities do not lead to market manipulation or insider trading [8][9] - A formal record of research interactions should be maintained, and any undisclosed significant information must be protected [9][10] - The company should actively engage with investors through various platforms, ensuring responses to inquiries are thorough and timely [10][11] Group 5: Organizational Structure and Responsibilities - The board secretary is responsible for coordinating investor relations management, supported by designated staff [11][12] - Key responsibilities include developing management policies, handling investor inquiries, and ensuring compliance with legal standards [12][13] - Staff involved in investor relations must possess relevant expertise and undergo regular training to enhance their skills [13][14]

江苏鱼跃医疗设备股份有限公司 环境、社会和公司治理(ESG)管理制度 第一章 总则 第二章 ESG 管理理念 第一条 为切实加强江苏鱼跃医疗设备股份有限公司(以下简称"公司")的环境、 社会和公司治理(以下简称"ESG")各项工作开展，进一步推动公司可 持续发展，持续提升公司治理能力、竞争能力、创新能力、抗风险能力 和回报能力，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司治理准则》《上市公司自律监管指引第 1 号——主板上市公 司规范运作》《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 17 号——可持续发展报告(试行)》等相关法律、 法规、规范性文件和《公司章程》的相关规定，结合公司实际情况，制 定本制度。 第二条 本制度所称的 ESG 职责，是指公司在经营发展过程中应当履行的环境 (Environmental)、社会(Social)和公司治理(Governance)方面的责任和 义务，主要包括对自然环境和资源的保护、社会责任的承担以及公司治 理的健全和透明。 第三条 本制度所称的利益相关方，是指其利益可能受到公司决策或经营活动影 响的组织或个人，包括股东(投资者 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-036 2024 年 11 月 15 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯 表决的方式召开了第六届董事会第八次临时会议。公司于 2024 年 11 月 10 日以书面送 达及电子邮件方式向公司全体董事发出了召开公司第六届董事会第八次临时会议的通 知以及提交审议的议案。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议的召 集、召开及表决等程序符合《中华人民共和国公司法》和《公司章程》的有关规定，会 议决议合法、有效。会议由董事长吴群先生主持，经与会董事充分讨论，审议通过了如 下议案： 二、董事会会议审议情况 1、关于《建立<江苏鱼跃医疗设备股份有限公司舆情管理制度>》的议案 表决结果：同意：9 票；反对：0 票；弃权：0 票 江苏鱼跃医疗设备股份有限公司 第六届董事会第八次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1 详细内容请见 2024 年 11 月 16 日巨潮资讯网（www.cninfo.com.cn）的《江苏鱼 ...

江苏鱼跃医疗设备股份有限公司 舆情管理制度 第一章 总则 第二章 舆情管理的组织架构与职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。有 第十条 各类舆情信息的应对原则： (一) 及时性：公司应保持对舆情信息的敏感度，快速反应、迅速行动， 避免事态扩大和负面影响加剧，掌握舆情应对的主动权； (二) 协同性：公司应加强内外部、各部门间的信息协同，确保相关信 息的一致性。 (三) 针对性：公司应根据舆情事件的性质、影响范围等特点制定针对 性方案，积极配合各方做好相关事宜。 (四) 审慎性：公司在舆情应对的过程中，应审慎核实舆情信息，不得 基于主观推测进行信息披露。 第十一条 各类舆情信息的报告流程： (一) 公司及子公司各部门有关人员在知悉舆情信息后应立即向董事 会秘书和舆情工作小组报告。 (二) 舆情工作小组第一时间核实相关信息，并初步评估事件事态的严 重性，如判断可能形成重大舆情，应当及时向舆情管理工作组报 告； (三) 董事会秘书在知悉上述舆情后，应在第一时间参与舆情的有关情 况调查，如判断舆情信息可能或已经对公司股票及其衍生品种交 易价格造成较大影响时，应当向舆情管理工作组组长报 ...

第一章 总则 江苏鱼跃医疗设备股份有限公司 对外投资管理制度 第一条 为了规范江苏鱼跃医疗设备股份有限公司(以下简称"公司"或"本公 司")对外投资行为，防范投资风险，提高对外投资效益，根据《中华人 民共和国公司法》(以下简称"《公司法》")《中华人民共和国证券法》 等法律法规以及《深圳证券交易所股票上市规则》(以下简称"《上市规 则》")《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》《深圳证券交易所上市公司自律监管指引第 7 号——交 易与关联交易》和《江苏鱼跃医疗设备股份有限公司章程》(以下简称 "《公司章程》")的相关规定，制定本制度。 第二条 公司对外投资行为必须符合国家有关法规及产业政策，符合公司发展战 略，有利于增强公司竞争能力，有利于合理配置企业资源，创造良好经 济效益，促进公司可持续发展。 第三条 本制度所称对外投资，是指公司在境内外进行的下列以盈利或保值增值 为目的的投资行为： (一) 向其他企业(含公司控股子公司)投资，包括单独设立或与他人共 同设立企业、对其他企业增资、受让其他企业股权等权益性投资； (二) 委托理财，是指公司委托银行、信托、证券、基金、期货、 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-035 江苏鱼跃医疗设备股份有限公司 关于 2023 年度员工持股计划首次受让部分 第一个锁定期届满的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）于 2023 年 9 月 12 日召开第五届董事会第二十五次临时会议和第五届监事会第十一次临 时会议，于 2023 年 9 月 28 日召开 2023 年第一次临时股东大会，审议通过了《江 苏鱼跃医疗设备股份有限公司 2023 年度员工持股计划（草案）及其摘要》等相 关议案。具体内容详见公司于 2023 年 9 月 13 日和 2023 年 9 月 29 日披露在《证 券时报》及巨潮资讯网（www.cninfo.com.cn）上的相关公告。 公司 2023 年度员工持股计划（以下简称"本次员工持股计划"）第一个锁 定期于 2024 年 11 月 16 日届满，根据《关于上市公司实施员工持股计划试点的 指导意见》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》的相 ...

Investment Rating - The report maintains a "Buy" rating for Yuyue Medical (002223) [2][8] Core Views - The company's revenue growth rate turned positive in the third quarter, with a year-on-year increase of 2.21%, indicating a return to a sustainable development trajectory [5][8] - The new generation Continuous Glucose Monitoring (CGM) products are experiencing rapid sales expansion, with significant potential for overseas markets [6][8] Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 6.028 billion yuan, a year-on-year decrease of 9.53%, and a net profit attributable to shareholders of 1.532 billion yuan, down 30.09% [4][8] - The third quarter alone saw a revenue of 1.720 billion yuan, with a net profit of 411 million yuan, reflecting a year-on-year decline of 40.95% [4][8] - The comprehensive gross margin for the first three quarters was 50.13%, a decrease of 1.44 percentage points year-on-year [7][8] Sales and Marketing Strategy - The company increased its sales expenses by 8.84% compared to the same period in 2023, focusing on enhancing brand influence and market share through aggressive marketing efforts [5][8] - The CGM product line is expected to drive growth, with ongoing efforts to expand into international markets, particularly in regions like Latin America, Africa, and Southeast Asia [6][8] Earnings Forecast - The company forecasts revenues of 8.129 billion yuan, 9.265 billion yuan, and 10.632 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 1.97%, 13.97%, and 14.75% [8][9] - The net profit attributable to shareholders is projected to be 2.018 billion yuan, 2.277 billion yuan, and 2.743 billion yuan for the same years, with growth rates of -15.76%, 12.79%, and 20.49% [8][9]